CefepimeThird Party Manufacturing in India

Cefepime works by binding to key penicillin-binding proteins to interrupt bacterial cell wall assembly during active cell replication, which triggers cell lysis. Its zwitterionic structure enables rapid outer membrane penetration in Gram-negative bacteria. This feature, combined with its high resistance to chromosome-mediated beta-lactamases, helps preserve its antimicrobial activity against many cephalosporin-resistant strains. Unlike older generation alternatives, it offers balanced, broad-spectrum coverage against both Gram-positive and Gram-negative pathogens. It is highly effective and well-tolerated.

Therapeutic Uses

• Empirical Monotherapy: Used for managing febrile neutropenic patients with suspected underlying systemic bacterial infections.
• Complicated Intra-Abdominal Infections: Combined with metronidazole to resolve deep peritoneal infections.
• Severe Nosocomial Pneumonia: Targets multi-drug resistant Pseudomonas strains in hospital intensive care environments.

Why Manufacturers Choose Cefepime

As a core fourth-generation cephalosporin, it serves as a reliable critical care option for managing broad-spectrum hospital infections. Choosing Cefepime third party manufacturing in India through Celesta helps ensure access to highly pure, reliable injectable formulations. Using high-grade CAS number 88040-23-7 material within our WHO-GMP certified partner facilities helps maintain long-term product stability and rapid reconstitution properties.